Get the Stockscreener App
0.2964
4.39%
-0.0136
Cellectar Biosciences Inc stock is traded at $0.2964, with a volume of 727.61K.
It is down -4.39% in the last 24 hours and down -11.47% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$0.31
Open:
$0.3007
24h Volume:
727.61K
Relative Volume:
0.67
Market Cap:
$13.37M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.0912
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+2.14%
1M Performance:
-11.47%
6M Performance:
-85.54%
1Y Performance:
-90.22%
1-Day Range:
$0.291
$0.3075
1-Week Range:
$0.291
$0.32
52-Week Range:
$0.224
$3.51
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2964 | 13.37M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated by Analysts at StockNews.com - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Analysis - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences Enhances CEO and COO Severance Benefits - TipRanks
What is Roth Capital’s Estimate for CLRB FY2029 Earnings? - Defense World
Earnings call transcript: Cellectar Biosciences Q4 2024 sees restructuring amid losses - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlight - GuruFocus
Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings - TipRanks
Cellectar Biosciences Advances Cancer Drug Pipeline - TipRanks
Cellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges - TipRanks
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update - GlobeNewswire
CELLECTAR BIOSCIENCES Earnings Results: $CLRB Reports Quarterly Earnings | CLRB Stock News - Quiver Quantitative
Cellectar's Breakthrough: 83.6% Response Rate Puts FDA Fast Track Within Reach - StockTitan
Cellectar Biosciences Provides Update on FDA Regulatory Path for Iopofosine I 131 in Waldenström Macroglobulinemia and Advances Phase 1 Trials for New Radioconjugates - Nasdaq
Cellectar Biosciences COO acquires $8,400 in stock By Investing.com - Investing.com Canada
Cellectar Biosciences COO acquires $8,400 in stock - Investing.com India
Cellectar Biosciences to Present at the 37th Annual Roth Conference - Quantisnow
Cellectar Biosciences Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Cellectar Biosciences, Inc. to Present at 37th Annual Roth Conference - Nasdaq
Cancer Treatment Breakthrough? Cellectar Biosciences Reveals Latest Progress at Major Investor Conference - StockTitan
Before You Invest, Make Sure You Check This Cellectar Biosciences Inc (NASDAQ: CLRB) Analysis - stocksregister.com
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 - GlobeNewswire
Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 - Nasdaq
When Will Cellectar Biosciences Reveal Its 2024 Financial Performance? - StockTitan
2 No-Brainer Stocks to Buy Now With $250 Before They Soar in 2025, According to Wall Street - AInvest
CLRB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Prepare Yourself for Liftoff: Cellectar Biosciences Inc (CLRB) - SETE News
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):